Nitta Gelatin India Ltd
Incorporated in 1975, Nitta Gelatin India Ltd manufactures and sells ossein, gelatin, and collagen peptide[1]
- Market Cap ₹ 1,503 Cr.
- Current Price ₹ 1,649
- High / Low ₹ 1,690 / 753
- Stock P/E 13.6
- Book Value ₹ 545
- Dividend Yield 0.36 %
- ROCE 31.3 %
- ROE 24.9 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 43.9% CAGR over last 5 years
Cons
- The company has delivered a poor sales growth of 10.7% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals
Part of BSE Commodities
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 355 | 357 | 341 | 343 | 261 | 294 | 354 | 429 | 487 | 473 | 527 | 588 | |
| 329 | 318 | 304 | 316 | 243 | 268 | 314 | 378 | 397 | 363 | 424 | 452 | |
| Operating Profit | 27 | 39 | 37 | 27 | 18 | 27 | 40 | 51 | 90 | 110 | 104 | 136 |
| OPM % | 8% | 11% | 11% | 8% | 7% | 9% | 11% | 12% | 18% | 23% | 20% | 23% |
| 2 | 2 | 9 | 5 | 1 | 3 | 5 | 6 | 5 | 17 | 22 | 26 | |
| Interest | 8 | 6 | 4 | 7 | 8 | 8 | 5 | 5 | 4 | 3 | 3 | 2 |
| Depreciation | 10 | 9 | 10 | 14 | 14 | 15 | 15 | 14 | 13 | 14 | 13 | 15 |
| Profit before tax | 10 | 26 | 32 | 11 | -4 | 7 | 24 | 38 | 78 | 110 | 110 | 146 |
| Tax % | 49% | 37% | 36% | 65% | -28% | -15% | 26% | 29% | 25% | 25% | 25% | 24% |
| 5 | 17 | 20 | 4 | -3 | 8 | 18 | 27 | 59 | 82 | 82 | 111 | |
| EPS in Rs | 5.62 | 18.38 | 22.57 | 4.16 | -2.91 | 8.70 | 19.72 | 29.30 | 64.72 | 90.86 | 90.55 | 121.81 |
| Dividend Payout % | 18% | 14% | 11% | 60% | -52% | 29% | 15% | 14% | 12% | 7% | 9% | 6% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 11% |
| 3 Years: | 7% |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 21% |
| 5 Years: | 44% |
| 3 Years: | 23% |
| TTM: | 51% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 26% |
| 5 Years: | 54% |
| 3 Years: | 25% |
| 1 Year: | 114% |
| Return on Equity | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 24% |
| 3 Years: | 25% |
| Last Year: | 25% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |
| Reserves | 113 | 125 | 130 | 138 | 133 | 134 | 154 | 176 | 231 | 307 | 383 | 486 |
| 53 | 70 | 84 | 104 | 101 | 79 | 75 | 80 | 33 | 27 | 45 | 9 | |
| 40 | 45 | 48 | 55 | 51 | 53 | 49 | 51 | 53 | 57 | 54 | 66 | |
| Total Liabilities | 214 | 249 | 271 | 305 | 295 | 276 | 287 | 316 | 326 | 400 | 492 | 570 |
| 77 | 80 | 77 | 110 | 126 | 116 | 108 | 102 | 109 | 106 | 111 | 149 | |
| CWIP | 8 | 7 | 11 | 10 | 3 | 4 | 2 | 7 | 7 | 8 | 19 | 14 |
| Investments | 32 | 45 | 27 | 4 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 |
| 96 | 117 | 157 | 181 | 161 | 151 | 172 | 202 | 206 | 281 | 357 | 403 | |
| Total Assets | 214 | 249 | 271 | 305 | 295 | 276 | 287 | 316 | 326 | 400 | 492 | 570 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 17 | 29 | 11 | 26 | 28 | 33 | 15 | 13 | 78 | 79 | 61 | 125 | |
| -8 | -22 | -3 | -7 | -13 | -7 | -3 | -11 | -15 | -44 | 2 | -176 | |
| -8 | 11 | -6 | -20 | -14 | -29 | -12 | -2 | -53 | -15 | 11 | -45 | |
| Net Cash Flow | 1 | 18 | 2 | -0 | 1 | -3 | -0 | -1 | 10 | 20 | 74 | -96 |
| Free Cash Flow | 8 | 18 | -4 | 12 | 12 | 24 | 8 | -1 | 58 | 67 | 37 | 73 |
| CFO/OP | 73% | 88% | 51% | 138% | 165% | 133% | 49% | 26% | 109% | 97% | 83% | 116% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 23 | 21 | 56 | 65 | 74 | 34 | 57 | 65 | 59 | 60 | 66 | 61 |
| Inventory Days | 99 | 112 | 127 | 151 | 202 | 220 | 161 | 148 | 133 | 164 | 138 | 120 |
| Days Payable | 50 | 43 | 37 | 56 | 67 | 58 | 46 | 30 | 45 | 53 | 38 | 54 |
| Cash Conversion Cycle | 72 | 90 | 147 | 160 | 210 | 196 | 172 | 182 | 148 | 171 | 165 | 127 |
| Working Capital Days | 17 | 18 | 35 | 29 | 18 | 18 | 50 | 52 | 72 | 82 | 75 | 84 |
| ROCE % | 11% | 17% | 17% | 7% | 2% | 6% | 13% | 17% | 31% | 37% | 26% | 31% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Export Share of Gelatin Sales % |
|
||||||||||
| Production Volume - Di-Calcium Phosphate (DCP) (Subsidiaries) MT |
|||||||||||
| Production Volume - Ossein (Subsidiaries) MT |
|||||||||||
| Export Share of Collagen Peptide Sales % |
|||||||||||
| Installed Capacity - Gelatin MT per year |
|||||||||||
| Gelatin Capacity Expansion Announced MT |
|||||||||||
| R&D Expenditure (Percentage of Turnover) % |
|||||||||||
Extracted by Screener AI
Documents
Announcements
-
Regulation 30 (LODR)- Appointment Of Senior Management Person
25 May - Board appointed Mr. Juby K. Mathews as Head-HR Designate on 25 May 2026.
-
Announcement under Regulation 30 (LODR)-Change in Directorate
25 May - Mr. V. Ranganathan re-appointed Independent Director from 03.08.2026 for three years, subject to shareholder approval.
-
Announcement under Regulation 30 (LODR)-Change in Directorate
25 May - Dr. Balu Paulose Maliakel appointed Additional Director, proposed Independent Director for five years from AGM.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
21 May - Submitted Annual Secretarial Compliance Report for FY2025-26; one prior 16-day filing delay noted.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
4 May - Copies of the Newspaper Advertisements published in English and Malayalam Newspapers pertaining to the Audited Financial Results of the Company for the quarter and financial …
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
NGIL, a joint venture between the Kerala State Industrial Development Corporation (32% shareholding) and Osaka-based NGI (43% stake), manufactures gelatin, ossein, limed ossein, and DCP from processed animal bones. It also produces collagen peptide-based consumer products for the pharmaceutical and healthcare industries.